Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04035447 · ClinicalTrials.gov registry record · NA

Symptom Management for YA Cancer Survivors

A NA study, sponsored by Duke University.

Completed
Registry status
NA
Development phase
65
Enrollment target

NCT04035447: Completed NA study, sponsored by Duke University.

NCT04035447 is a NA study that has completed, run by Duke University. The registered enrollment target is 65 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04035447, a NA study, has completed, sponsored by Duke University.

COMPLETED
Registry status
NA
Development phase
65 participants
Enrollment target

Study Summary

Symptom interference is common for survivors of young adult cancer (aged 18-39 at diagnosis) and impacts their abilities to achieve normative life goals (e.g., education, careers, independence, romantic/social relationships) as well as adhere to recommended follow-up care. Assistance with symptom management has been rated by young adult survivors as an important and unmet healthcare need; however, skill-based symptom management interventions have typically been tested among older cancer survivors and have not targeted the unique developmental needs of those diagnosed as young adults. The proposed research advances the health and wellbeing of young adult cancer survivors by creating a developmentally appropriate hybrid in-person/mHealth behavioral symptom management intervention which addresses variables (i.e., symptoms and symptom interference) consistently linked to significant social, economic, and health burden.

Primary Outcome

Intervention satisfaction will be assessed using the Satisfaction witth Therapy and Therapist Scale-Revised, a 13-item measure with the first 12-items on a five-point scale ranging from 1 "strongly disagree" to 5 "strongly agree." The 13th item (Global Improvement) asks, "How much did the intervention help with your symptoms?" with 5 answer choices ranging from "made things a lot better" (1) to "made things a lot worse" (5). Each of the subscales (Satisfaction With Therapy and Satisfaction With

Interventions

  • BEHAVIORAL Behavioral Symptom Management for Young Adult Cancer Survivors

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2020-01-22
Est. Completion 2024-06-15
Phase NA
Duke University

1,725 total trials

What the finished NCT04035447 record still lists

NCT04035447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which Behavioral Symptom Management for Young Adult Cancer Survivors is the first listed.

NCT04035447 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04035447 about?

NCT04035447 is a clinical study titled "Symptom Management for YA Cancer Survivors". Symptom interference is common for survivors of young adult cancer (aged 18-39 at diagnosis) and impacts their abilities to achieve normative life goals (e.g., education, careers, independence, romantic/social relationships) as well as adhere to recommended follow-up care. Assistance with symptom ma...

What is the current status of trial NCT04035447?

This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2020-01-22. Estimated completion is 2024-06-15.

What interventions are being tested in trial NCT04035447?

The interventions under investigation include: Behavioral Symptom Management for Young Adult Cancer Survivors (BEHAVIORAL).

Who is sponsoring clinical trial NCT04035447?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04035447's enrollment target sits among peer trials

65 1144th of 2000 higher than 854 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04035447, the US trial registry maintained by the National Library of Medicine. NCT04035447 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.